Clinical efficacy of neoadjuvant chemotherapy by docetaxe combined with epirubicin on triple negative breast cancer patients
10.13699/j.cnki.1001-6821.2015.24.003
- VernacularTitle:多西紫杉醇和表阿霉素新辅助化疗对三阴性乳腺癌的临床疗效评价
- Author:
Wei GUO
1
;
Gong-Sheng JIN
Author Information
1. 蚌埠医学院 第一附属医院 肿瘤外科
- Keywords:
triple negative breast cancer;
neoadjuvant chemotherapy;
docetaxel;
epirubicin
- From:
The Chinese Journal of Clinical Pharmacology
2015;(24):2381-2383
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of neoadjuvant chemotherapy regimen of docetaxel combined with epirubicin in the treatment of triple negative breast cancer.Methods Sixty-one triple negative breast cancer patients were divided into experiment group (n=29) and control group (n=32).Patients in experiment group were treated with docetaxel 75 mg? m-2 intervenous drop infusion for 3 h, epirubicin 60 mg? m-2 intervenous drop infusion, 3 weeks a cycle for 3 cycles.Patients in control group were treated with cyclophosphamide 600 mg? m-2 , epirubicin 80 mg? m-2 and fluorouracil 500 mg? m-2 intervenous drop infusion, 3 weeks a cycle for 3 cycles.The clinical efficacy and adverse reaction were compared between the two groups. And the operation was taken for all the patients.Results The objective response rate were 75.9%and 40.6%in experiment and control group, which had a significant difference ( P <0.05 ) . But the pathology complete response were 2 and 0 for the experiment and control group which had no statistical difference between the two groups ( P>0.05 ) . A total of 18 cases of grade Ⅱ/Ⅲgastrointestinal reaction and 16 cases of grade Ⅱ/Ⅲ hematological toxicity were found in experiment group, and 19 cases of grade Ⅱ/Ⅲ gastrointestinal reaction, 21 cases of grade Ⅱ/Ⅲ hematological toxicity and 1 cases of grade grade of Ⅳ hematological toxicity were found in control group.The incidence rate of adverse reactions were not statistically different between the two groups (P>0.05).Conclusion The docetaxel combined with epirubicin regimen was superior to cyclophosphamide, epiru-bicin and fluorouracil regimen.
